BiotechTube
Berlin Heals

Berlin Heals

Zurich, Switzerland· Est.
berlinheals.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $37M

Overview

Berlin Heals is a private, pre-revenue medical device innovator targeting the large and growing heart failure market. Its core technology is the Cardiac Contractility Modulation (CCM) implant, designed to improve the heart's pumping strength in patients with reduced ejection fraction. The company is advancing its device through clinical development in Europe, positioning itself in a competitive landscape dominated by pharmaceutical and device-based therapies. Success hinges on clinical validation, regulatory approval, and eventual market adoption against established treatments.

CardiovascularHeart Failure

Technology Platform

Cardiac Contractility Modulation (CCM) via an implantable pulse generator delivering non-excitatory electrical signals to enhance heart muscle contractility.

Funding History

2
Total raised:$37M
Series B$25M
Series A$12M

Opportunities

The global heart failure device market is large and growing, with a significant unmet need for patients who remain symptomatic on drugs and are ineligible for CRT.
Successful clinical validation could position the CCM device as a unique, gap-filling therapy.
A clear path to CE Mark and eventual FDA approval offers substantial value-creation milestones for investors.

Risk Factors

High clinical risk that the device fails to show meaningful efficacy in pivotal trials.
Intense competition from both evolving pharmaceutical regimens and established device therapies.
Significant regulatory and reimbursement hurdles in key markets like the EU and US.

Competitive Landscape

Berlin Heals competes in the broad heart failure market dominated by large pharma (Novartis, AstraZeneca) and medtech giants (Medtronic, Abbott, Boston Scientific). Its specific CCM technology faces competition from other companies exploring cardiac contractility modulation, as well as from alternative device approaches like baroreceptor activation therapy and newer iterations of CRT.

More companies in Switzerland →